These and other factors arising from the COVID-19 pandemic
could worsen in countries that are already afflicted with COVID-19, could continue to spread to additional countries, or could return to countries where the pandemic has been partially contained, each of which
could further adversely impact our ability to conduct clinical trials and our business generally, and could have a material adverse impact on our operations and financial condition and results.
In addition, the trading prices for our common stock and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 epidemic. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. The COVID-19 outbreak
continues to rapidly evolve. The extent to which the outbreak may impact our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the
ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries,
business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.
Please also refer to the complete Item 1A of the Companys Annual Report on Form 10-K filed with the
Securities and Exchange Commission on February 26, 2020 for additional risks and uncertainties facing the Company that may have a material adverse effect on the Companys business prospects, financial condition and results of operations.
Forward-Looking Statements
This Current
Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange
Act). Forward-looking statements are usually identified by the use of words such as anticipates, believes, estimates, expects, intends, may, plans,
projects, seeks, should, will, and variations of such words or similar expressions. Eidos intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements
regarding the timing of enrollment in its clinical trials, delays in the commencement of its planned clinical trials and non-clinical experiments, its development strategy for its product candidates, the
timing, progress and results of clinical trials, preclinical studies and other research and development activities and the potential utility of its product candidates, and the impact of COVID-19 on its
preclinical studies, clinical trials, business, financial condition and results of operations, reflect Eidos current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently
available to Eidos and on assumptions it has made. Although Eidos believes that its plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, Eidos can give no
assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks,
uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of Eidos most recent Annual Report on Form 10-K and its other Securities and Exchange
filings. Moreover, Eidos operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of Eidos management as
of the date of this Current Report on Form 8-K, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
Except as required by applicable law, Eidos assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.